Real World Insights: Bispecific Antibodies in R/R MM : Episode 11
Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel
Panelists discuss how, for a patient who has an aggressive disease, physicians will plan for monthly serum markers including serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE); if they start seeing an increase in the disease, they plan an imaging for bone marrow biopsy and consider a diagnostics lumbar puncture.
Video content above is prompted by the following:
- What would your follow-up monitoring plan look like to assess both CNS and systemic responses to elranatamab?
- What treatment sequencing strategy would you use if disease progression occurs, particularly balancing the need for CNS efficacy and minimizing systemic toxicity?
- Given the response he has made on elranatamab, how would you counsel him on the potential benefits and risks of continuing vs sequencing to cilta-cel?
Recent Videos
Related Content
